Register for ALS Clinical Trials Unboxed

On Wednesday, September 30, 2026 at 1 p.m. ET, join ALS Canada for our next ALS Clinical Trials Unboxed webinar to learn more about ongoing ALS clinical trials.

Join Dr. Angela Genge as she shares results from the Phase 2 AP-101-02 study, including safety, biomarker and clinical findings from up to 48 weeks of treatment. Dr. Genge will also discuss AP-101, an investigational therapy designed to target toxic SOD1 protein in ALS, and provide an update on plans for a Phase 3 clinical trial in 2027.

First Name

Last Name

Email Address

City

Province

Would you please share how you are connected to the ALS community?

Please submit your questions (optional)

I give permission for the ALS Society of Canada to email me about its activities and how I can support its work toward a world free of ALS.

Yes, I want to subscribe

No, unsubscribe me

Please note that ALS Canada does not provide medical advice or make referrals related to drug therapies or alternative therapies. These questions should be discussed directly with a medical professional – ideally an ALS neurologist, who would be qualified to interpret clinical information for individual situations.

Please visit our list of ALS clinics to help you to connect with a clinic in your area.